Form 4: Neurocrine Biosciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Neurocrine Biosciences' Chief Regulatory Officer, Ingrid Delaet, executed stock options and sold shares according to a pre-arranged 10b5-1 trading plan.

Summary

• Ingrid Delaet, Chief Regulatory Officer at Neurocrine Biosciences, engaged in transactions involving the company's stock on December 31, 2024.
• She exercised 272 non-qualified stock options at a price of $79.02 per share.
• Following the exercise, she sold 272 shares of common stock at $138.10 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2023.
• After these transactions, Ms. Delaet directly owns 2,507 shares of common stock and 2,718 non-qualified stock options.

Sentiment

Score: 6

Explanation: The document reflects routine transactions by an executive under a pre-arranged plan. It is neither particularly positive nor negative, but rather a standard practice.

Positives

• The use of a 10b5-1 trading plan indicates a structured and pre-planned approach to stock transactions, which can reduce concerns about insider trading.

Risks

• Executive stock sales, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This type of transaction is common for executives at publicly traded companies, especially those with stock-based compensation. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology sector such as Amgen, Biogen, and Gilead Sciences.
• These plans allow executives to sell shares in a pre-planned manner, avoiding potential accusations of insider trading.
• The vesting schedule of the options, with monthly installments over several years, is also a typical practice for executive compensation packages in the industry.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they represent a small portion of the total outstanding shares.
• The use of a 10b5-1 plan provides transparency and reduces concerns about insider trading.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, stock options, insider trading, 10b5-1 plan, executive compensation, stock sale, regulatory officer